Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :737
Small font sizeDefault font sizeIncrease font size
Navigate here
  Search
 
  
Resource links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (188 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article

 Article Access Statistics
    Viewed101    
    Printed2    
    Emailed0    
    PDF Downloaded26    
    Comments [Add]    

Recommend this journal

 

  Table of Contents  
MCQS
Year : 2019  |  Volume : 56  |  Issue : 4  |  Page : 348-349
 

MCQs on “Analysis of postoperative radiotherapy effects within risk groups in patients with FIGO I, II, and III endometrial cancer”


1 Department of Medical Oncology and Hemato-Oncology, Narayana Superspeciality Hospital, Gurugram, Haryana, India
2 Department of Radiation Oncology, Artemis Hospital, Gurugram, Haryana, India
3 Department of Surgical Oncology, Command Hospital, Bangalore, Karnataka, India

Date of Web Publication11-Oct-2019

Correspondence Address:
H S Darling
Department of Medical Oncology and Hemato-Oncology, Narayana Superspeciality Hospital, Gurugram, Haryana
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijc.IJC_868_19

Rights and Permissions



How to cite this article:
Darling H S, Jayalakshmi S, Jaiswal P. MCQs on “Analysis of postoperative radiotherapy effects within risk groups in patients with FIGO I, II, and III endometrial cancer”. Indian J Cancer 2019;56:348-9

How to cite this URL:
Darling H S, Jayalakshmi S, Jaiswal P. MCQs on “Analysis of postoperative radiotherapy effects within risk groups in patients with FIGO I, II, and III endometrial cancer”. Indian J Cancer [serial online] 2019 [cited 2019 Nov 18];56:348-9. Available from: http://www.indianjcancer.com/text.asp?2019/56/4/348/268966




1: Risk factors for endometrial cancer are all except

(a) Age >60 years

(b) Obesity

(c) Smoking

(d) Early menarche, late menopause

2: At the time of diagnosis, what percentage of patients has FIGO stage IV B?

(a) 8%

(b) 12%

(c) 16%

(d) 20%

3: In the present study, which factor was not significantly associated with time to progression?

(a) Adjuvant radiotherapy

(b) Number of deliveries

(c) FIGO stage

(d) Comorbidities

4: The role of adjuvant chemotherapy in this study was

(a) Increased PFS but no OS

(b) Increased PFS as well as OS

(c) There was no impact on survival

(d) Chemotherapy was not used in this study

5: Maximum percentage of patients was from which risk group?

(a) Low risk

(b) Moderate risk

(c) Medium risk

(d) High risk

6: Major limitations of this study were all except

(a) Single center study

(b) Small sample size

(c) Elderly population

(d) Toxicities were nor reported

7: Median OS in this study was

(a) 80 months

(b) 41.5 months

(c) 52 months

(d) 21.5 months

8: Most common family history was

(a) Malignancy

(b) Epilepsy

(c) Cardiac disease

(d) Kidney disease

9: Maximum overall survival according to localization of distant metastases was found in patients with

(a) Lung only metastases

(b) Liver only metastases

(c) Simultaneous liver and bone metastases

(d) Bone only metastases

10: The incorrect statement about radiotherapy (RT) modality used is

(a) The smallest number of patients received transcutaneous RT

(b) Maximum patients received intracavitary brachytherapy

(c) These details are not available

(d) Maximum patients received transcutaneous RT plus intracavitary brachytherapy

Answers and explanations

1: (c)

Risk factors for endometrial cancer are age (over 60 years), obesity, diabetes, hypertension, hyperthyroidism, early menarche, and late menopause, larger number and longer duration of menstrual cycles, multiparity, infertility, irregular menstrual cycles due to lack of ovulation, presence of hormone-dependent breast cancer, and other.

2: (a)

At the time of diagnosis, about 8% of patients have distant metastases.

3: (b)

Comorbidities (P = 0.033), FIGO stage (P = 0.000), metastases localization (P = 0.039), adjuvant radiotherapy (P = 0.031), and late toxicity organ site (P = 0.013) had significant influence on time to progression.

4: (d)

The exclusion criteria were unknown stage/grade, systemic chemotherapy application, previous pelvic radiotherapy, and radiotherapy initiated more than 7 weeks after surgery.

5: (b)

[Table 2], Low risk 18 (22.5%), moderate risk 31 (37.5%), medium risk 23 (28.8%), high risk 9 (11.3%).

6: (d)

Limitations of our study were that the study was conducted in a single center and on a small sample of patients. In addition, majority of patients were older than age 65 years.

7: (b)

OS for a 5-year period was 80%, whereas the median OS was 41.5 months (range, 1-60).

8: (a)

[Table 1]. Family history: Negative 11 (13.8%), malignant diseases 32 (40.0%), cardiac diseases 18 (22.5%), epilepsy 6 (7.5%), allergic diseases 5 (6.3%), kidney diseases 5 (6.3%), and no data 3 (3.8%).

9: (d)

[Figure 3], (d) Overall survival according to localization of distant metastases.

10: (d)

[Table 3]. Transcutaneous + intracavitary brachytherapy (76.3%).






 

Top
Print this article  Email this article
 

    

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow